Nonetheless, our in vivo data using Fam13a-/- mice clearly showed that loss of FAM13A exacerbated pulmonary hypertension, and thus FAM13A is an attractive pharmacotherapeutic target for the treatment of pulmonary hypertension. This evidence concerns the gene FAM13A and pulmonary hypertension.